Esophageal Cancer Treatment Market is expected to reach US$ 2.66 billion by 2033 | Major players - Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Novartis AG.

Market Size and Growth:

The Global Esophageal Cancer Treatment Market Size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.66 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/esophageal-cancer-treatment?sz

The Esophageal Cancer Treatment Market encompasses therapies, drugs, and medical interventions aimed at managing and treating esophageal cancer. It includes chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical procedures. The market focuses on improving patient survival, reducing complications, and enhancing quality of life, driven by rising cancer prevalence, technological advancements, and increasing awareness of early diagnosis and personalized treatment approaches.

United States: Recent Developments of Esophageal Cancer Treatment Market

✅ October 2025: The U.S. Food and Drug Administration granted approval for Opdivo (nivolumab) and combination therapy Opdivo plus Yervoy (ipilimumab) for advanced or metastatic esophageal squamous cell carcinoma (ESCC), based on Phase 3 clinical trial data showing improved overall survival.​

✅ November 2025: The growing pipeline of novel targeted therapies and immunotherapies is expanding, with advancements in personalized medicine and early diagnosis driving robust market growth. Strategic collaborations among pharma companies underpin expansion in the U.S. market.​

✅ December 2025: The North America esophageal cancer market continues to be supported by high healthcare expenditure, leading to increased access to effective cancer care and innovations, fueling further investments in immunotherapies and chemotherapy regimens.

Europe: Recent Developments of Esophageal Cancer Treatment Market

✅ October 2025: Europe is seeing rapid adoption of personalized medicine and precision oncology approaches, including immunotherapies and targeted agents, supported by advanced healthcare infrastructure and AI-driven drug discovery.​

✅ November 2025: Several novel esophageal cancer therapies are in clinical trials, including drugs like CHS-114, IKS014, HLX43, and others, expected to impact the European market significantly in the coming years.​

✅ December 2025: Growth in Europe is driven by government-backed cancer prevention programs, increasing disease awareness, and improvements in diagnostic technologies such as molecular diagnostics and blood-based biomarkers.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/esophageal-cancer-treatment?sz

Recent Regulatory / FDA Approvals & Diagnostics Advances in 2025:

✅ Tevimbra (tislelizumab‐jsgr): In March 2025, the U.S. Food and Drug Administration (FDA) approved Tevimbra, in combination with platinum‐based chemotherapy, as a first‐line treatment for adults with unresectable or metastatic Esophageal Squamous Cell Carcinoma (ESCC) whose tumors express PD-L1. The approval was based on phase‐3 trial data showing improved overall survival (median OS ~16.8 vs 9.6 months for chemo alone).

✅ Continued use & expansion of immunotherapy-based regimens: The approval of Tevimbra underscores a broader shift in esophageal cancer care toward immunotherapy + chemotherapy combinations. Experts note that immunotherapies are increasingly replacing or augmenting traditional chemotherapy in advanced/ metastatic settings.

✅ Better diagnostics: BE-SmartTM esophageal cancer test by ProPhase Labs, Inc. - In August 2025, the U.S. Patent Office granted a patent for this biomarker‐based system that assesses progression risk in people with precancerous conditions (e.g. Barrett's esophagus) and esophageal adenocarcinoma.

Mergers, Acquisitions & Strategic Deals - Market Consolidation in 2025:

✅ Bristol‐Myers Squibb (BMS) acquires esophageal‐cancer assets from BeiGene, Ltd. - In June 2025, BMS acquired BeiGene's oncology assets related to esophageal cancer therapeutics. This move strengthens BMS's immuno‐oncology portfolio and expands its presence in Asia‐Pacific markets.

✅ The acquisition reflects a strategic consolidation in the esophageal cancer drug market - combining R&D efforts, leveraging existing drug approvals (such as Tevimbra), and potentially optimizing global development and commercialization pathways.

Major Players:

Key companies in the Esophageal Cancer Treatment market include:

Merck & Co., Inc.
Bristol-Myers Squibb Company
BeiGene, Ltd.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Daiichi Sankyo, Inc.
Taiho Oncology, Inc.
Astellas Pharma Inc.
Novartis AG
Amgen, Inc.

Segments Covered in the Esophageal Cancer Treatment Market:

By Cancer Type: Squamous Cell Carcinoma, Adenocarcinoma.

By Treatment Type: Surgery, Chemotherapy, Radiation Therapy, Targeted Drug Therapy, Immunotherapy, Combination Therapy, Others.

By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Others.

Regional Analysis for Esophageal Cancer Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=esophageal-cancer-treatment

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Esophageal Cancer Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Esophageal Cancer Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Esophageal Cancer Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Esophageal Cancer Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Esophageal Cancer Treatment market?

➠ Who are the global key manufacturers of the Esophageal Cancer Treatment Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Esophageal Cancer Treatment market opportunities and threats faced by the vendors in the global Esophageal Cancer Treatment Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Esophageal Cancer Treatment market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.